Addendum

Sacituzumab govitecan (breast cancer) - Addendum to Commission A21-154

Status
Status: Commission completed
Project no.
A22-41
Last updated

Report documents

  1. Addendum

    Sacituzumab govitecan (breast cancer) - Addendum to Commission A21-154

    published on
    Document type
    PDF document, 330 kB, EN, not accessible

Dossier assessment

Indication:

Adult patients with unresectable or metastatic triple-negative breast cancer who have had two or more prior systemic therapies including at least one of them for advanced disease

Result of dossier assessment:

After addendum now indication of major added benefit

Additional information

Federal Joint Committee (G-BA)

2022-05-20 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A22-41
Commission
Commission awarded on 13.04.2022 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Connected Projects

  1. Dossier assessment

    Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-154
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form